Drug Resistance Mechanisms and Strategies of EGFR/ALK Targeted Therapy in Non-Small Cell Lung Cancer

View Full Paper

Ask AI

Bookmark

Drug resistance mechanisms significantly limit the effectiveness of EGFR and ALK targeted therapies in NSCLC.
Primary resistance includes mutations like EGFR exon 20 insertions and ALK fusion variant heterogeneity.
Current strategies to counteract resistance involve next-generation inhibitors like osimertinib.
Ongoing challenges in treatment include managing complex resistance and toxicity, while future directions aim at enhancing therapeutic innovation.

Discussion

No takes yet. Share an insight, caveat, or question.

This review summarizes mechanisms of drug resistance in NSCLC and current strategies for overcoming EGFR and ALK therapy challenges.

Yanwei Wang (2025) studied this question.

View Full Paper

Ask AI

Bookmark